Analyzing the therapeutic and preventive potential of probiotics in Alzheimer’s disease: a scoping review
Exploration of Neuroprotective Therapy · 2025
DOI: 10.37349/ent.2025.1004120 ↗Kurz gefasst
Scoping Review in der Zeitschrift Exploration of Neuroprotective Therapy, 2025. Verfasst von Adnan Akhtar Shaikh und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, neuroinflammation, and accumulation of amyloid-beta plaques and tau tangles. Emerging research emphasizes the gut-brain axis as a key modulator of AD pathogenesis, with gut microbiota influencing neuroimmune, neurochemical, and metabolic pathways. This review examines the therapeutic and preventive potential of probiotics, live beneficial microorganisms, in modulating the gut-brain axis to mitigate AD progression. Modifying gut microbiota presents a novel, potentially modifiable approach to influence AD pathophysiology and improve cognitive outcomes, offering insights for adjunctive clinical strategies. A systematic literature search was conducted across PubMed, Scopus, Web of Science, Google Scholar, and Cochrane Library for studies published up to July 2025. Studies were classified by design, sample size, follow-up duration, cognitive and biomarker outcomes, and risk of bias, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines to ensure transparency and reproducibility. Preclinical studies indicate that probiotics can regulate gut microbiota, reduce oxidative stress, suppress neuroinflammation, and enhance synaptic plasticity, improving cognition in animal models. Clinical trials suggest potential benefits in humans, including improved memory scores and reduced inflammatory biomarkers, though limited sample sizes, trial duration, and strain variability constrain conclusions. Overall, probiotics demonstrate promise as an adjunctive intervention in AD. Further long-term, strain-specific, and large-scale clinical studies are needed to confirm efficacy, establish causality, and optimize therapeutic strategies.
Zitieren
APA
Shaikh, A. A., Wilkhoo, H. S., Pillai, A., Thomas, S., Singh, B., & Nair, N. (2025). Analyzing the therapeutic and preventive potential of probiotics in Alzheimer’s disease: a scoping review. Exploration of Neuroprotective Therapy. https://doi.org/10.37349/ent.2025.1004120
Vancouver
Shaikh AA, Wilkhoo HS, Pillai A, Thomas S, Singh B, Nair N. Analyzing the therapeutic and preventive potential of probiotics in Alzheimer’s disease: a scoping review. Exploration of Neuroprotective Therapy. 2025. doi:10.37349/ent.2025.1004120
BibTeX
@article{Shaikh2025,
author = {Shaikh, Adnan Akhtar and Wilkhoo, Harsahaj Singh and Pillai, Ashwini and Thomas, Saira and Singh, Bharat and Nair, Niveditha},
title = {Analyzing the therapeutic and preventive potential of probiotics in Alzheimer’s disease: a scoping review},
journal = {Exploration of Neuroprotective Therapy},
year = {2025},
doi = {10.37349/ent.2025.1004120}
}
EUVIMED